phenyl (5-methylpyridin-2-yl)carbamate | 939969-06-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenyl (5-methylpyridin-2-yl)carbamate
• 英文别名: (5-methyl-pyridin-2-yl)-carbamic acid phenyl ester；phenyl N-(5-methylpyridin-2-yl)carbamate
• CAS: 939969-06-9
• 化学式: C₁₃H₁₂N₂O₂
• 分子量: 228.25
• InChiKey: UAZCYZQFKBJLDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  phenyl (5-methylpyridin-2-yl)carbamate 在 盐酸 、 氨 、 potassium carbonate 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 51.33h， 生成 tert-butyl 4-(4-(1-cyclopentyl-3-(5-methylpyridin-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate
  参考文献：
  名称：

  TW2023/4908

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氨基-5-甲基吡啶 、 氯甲酸苯酯 在 吡啶 、 盐酸 作用下， 以 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 生成 phenyl (5-methylpyridin-2-yl)carbamate
  参考文献：
  名称：

  Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines

  摘要：

  提供了能够调节NPY5受体活性的替代螺环[异苯并呋喃-1,4′-哌啶]-3-酮和3H-螺环异苯并呋喃-1,4′-哌啶。这些化合物可用于在体内或体外调节NPY5受体的配体结合，并且在治疗各种疾病（例如，肥胖或暴食症等进食障碍、精神障碍、糖尿病和高血压等心血管疾病）方面对人类、驯养的伴侣动物和家畜动物特别有用。提供了用于治疗这些疾病的药物组合物和方法，以及用于检测NPY5受体的这些化合物的方法。

  公开号：

  US20030036652A1

文献信息

• Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
  申请人：Bakthavatchalam Rajagopal

  公开号：US20050033048A1

  公开（公告）日：2005-02-10

  Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and method for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.

  本文提供了能够调节NPY5受体活性的取代的spiro[异苯并呋喃-1,4'-哌啶]-3-酮和3H-spiro异苯并呋喃-1,4'-哌啶。这些化合物可以用于体内或体外调节NPY5受体的配体结合，并且在人类、宠物和家畜动物的多种疾病治疗中特别有用（例如，饮食失调如肥胖症或贪食症、精神障碍、糖尿病和心血管疾病如高血压）。提供了制药组合物和治疗这些疾病的方法，以及使用这些化合物检测NPY5受体的方法。
• Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
  申请人：Pfizer Inc.

  公开号：US06566367B2

  公开（公告）日：2003-05-20

  Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.

  本发明提供了能够调节NPY5受体活性的取代的螺[异苯并呋喃-1,4'-哌啶]-3-酮和3H-螺异苯并呋喃-1,4'-哌啶类化合物。这些化合物可用于体内或体外调节配体与NPY5受体的结合，并在治疗多种疾病（例如，饮食失调，如肥胖症或贪食症，精神障碍，糖尿病和心血管疾病，如高血压）的人类、家养伴侣动物和家畜动物中特别有用。还提供了用于治疗这些疾病的制药组合物和方法，以及用于检测NPY5受体的方法。
• Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
  申请人：De Lombaert Stéphane

  公开号：US06943199B2

  公开（公告）日：2005-09-13

  Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.

  提供了能够调节NPY5受体活性的代替的spiro [异苯并呋喃-1,4'-哌啶] -3-酮和3H-spiroisobenzofuran-1,4'-哌啶。这些化合物可以用于体内或体外调节配体结合到NPY5受体，并在人类、家养伴侣动物和家畜动物的多种疾病治疗中特别有用（例如，饮食失调，如肥胖或贪食症，精神障碍、糖尿病和心血管疾病，如高血压）。提供了用于治疗这些疾病的药物组合物和方法，以及用于检测NPY5受体的这些化合物的方法。
• PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
  申请人：Bayer HealthCare LLC

  公开号：US20130225809A1

  公开（公告）日：2013-08-29

  This invention relates to pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.

  本发明涉及吡咯烷三氮唑化合物、含有这种化合物的药物组合物以及这些化合物和组合物在预防和/或治疗与血管生成相关的过度增殖性疾病方面的使用。
• HETEROCYCLIC COMPOUNDS
  申请人：SHIONOGI & CO., LTD.

  公开号：US20140249159A1

  公开（公告）日：2014-09-04

  The invention relates to compounds of Formula I: wherein Ar 1 , Ar 2 , Ar 3 , L 1 , L 2 , Y, Z and v are defined in the specification, and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof.

  本发明涉及式I的化合物：其中Ar1，Ar2，Ar3，L1，L2，Y，Z和v在说明书中有定义，以及其药学上可接受的衍生物，包括含有式I的化合物或其药学上可接受的衍生物的有效量的组合物，以及治疗或预防疼痛，尿失禁，溃疡，炎症性肠病和肠易激综合征等疾病的方法，包括向需要治疗的动物中给予式I的化合物或其药学上可接受的衍生物的有效量。